Levobetaxolol

Levobetaxolol
Clinical data
AHFS/Drugs.com	Micromedex Detailed Consumer Information
Routes of; administration	topical (ophthalmic)
ATC code	none;
Pharmacokinetic data
Elimination half-life	20 hours
Identifiers
	show IUPAC name
CAS Number	93221-48-8 ;
PubChem CID	60657;
IUPHAR/BPS	8035;
ChemSpider	54669 ;
UNII	75O9XHA4TU;
ChEBI	CHEBI:59254 ;
ChEMBL	ChEMBL1201274 ;
CompTox Dashboard (EPA)	DTXSID30239341 ;
Chemical and physical data
Formula	C18H29NO3
Molar mass	307.434 g·mol−1
3D model (JSmol)	Interactive image;
	show SMILES
	show InChI
	(what is this?)

Levobetaxolol is a drug used to lower the pressure in the eye in treating conditions such as glaucoma. It is marketed as a 0.25 or 0.5% ophthalmic solution of levobetaxolol hydrochloride under the trade name Betaxon. Levobetaxolol is a beta-adrenergic receptor inhibitor (beta blocker).

Indications[]

It is indicated for intraocular pressure reduction in patients with open-angle glaucoma or ocular hypertension.^[1]

Effect[]

Levobetaxolol inhibits the beta-1-adrenergic receptor. When applied topically, it reduces intra-ocular pressure (IOP) by 16-23% depending on time of day and the individual. It also has neuroprotective effects.^[1] Levobetaxolol has fewer cardiovascular side effects than other beta blockers.

Contraindications and side effects[]

Levobetaxolol should not be used by people who have sinus bradycardia, atrioventricular block, cardiogenic shock, or overt cardiac failure. The drug has been associated with bradycardia and hypertension.^{[citation needed]}

History[]

Levobetaxolol was developed in the 1980s.^[1] It was FDA approved in 2000.^[2]

References[]

^ Jump up to: ^a ^b ^c Quaranta L, Turano R, Pizzolante T (June 2007). "Levobetaxolol hydrochloride: a review of its pharmacology and use in the treatment of chronic open-angle glaucoma and ocular hypertension". Clinical Ophthalmology. 1 (2): 93–7. PMC 2704505. PMID 19668496.
^ "Betaxon New FDA Drug Approval | CenterWatch". www.centerwatch.com. Retrieved 11 April 2019.

[levo-1] Jump up to: ^a ^b ^c Quaranta L, Turano R, Pizzolante T (June 2007). "Levobetaxolol hydrochloride: a review of its pharmacology and use in the treatment of chronic open-angle glaucoma and ocular hypertension". Clinical Ophthalmology. 1 (2): 93–7. PMC 2704505. PMID 19668496.

[2] "Betaxon New FDA Drug Approval | CenterWatch". www.centerwatch.com. Retrieved 11 April 2019.

[1]

[2]

show v t Beta blockers (C07)
β, non-selective	Alprenolol Bopindolol Bupranolol Carteolol Cloranolol Mepindolol Nadolol Oxprenolol Penbutolol Pindolol/Iodopindolol Propranolol^# Sotalol Tertatolol Timolol^#
β₁-selective	Acebutolol Atenolol Betaxolol Bevantolol Bisoprolol^# Celiprolol Epanolol Esmolol Landiolol Metoprolol Nebivolol Practolol Talinolol
β₂-selective	Butaxamine
α₁- + β-selective	Arotinolol Carvedilol Labetalol
^#WHO-EM ^‡Withdrawn from market Clinical trials: ^†Phase III ^§Never to phase III

Clinical data


AHFS/Drugs.com	Micromedex Detailed Consumer Information
Routes of administration	topical (ophthalmic)
ATC code	none
Pharmacokinetic data
Elimination half-life	20 hours
Identifiers
show IUPAC name (S)-1-[p-[2-(cyclopropylmethoxy)ethyl]phenoxy]-3-(isopropylamino)-2-propanol hydrochloride
CAS Number	93221-48-8^N
PubChem CID	60657
IUPHAR/BPS	8035
ChemSpider	54669^Y
UNII	75O9XHA4TU
ChEBI	CHEBI:59254^Y
ChEMBL	ChEMBL1201274^N
CompTox Dashboard (EPA)	DTXSID30239341
Chemical and physical data
Formula	C₁₈H₂₉NO₃
Molar mass	307.434 g·mol⁻¹
3D model (JSmol)	Interactive image
show SMILES O(CCc1ccc(OC[C@@H](O)CNC(C)C)cc1)CC2CC2
show InChI InChI=1S/C18H29NO3/c1-14(2)19-11-17(20)13-22-18-7-5-15(6-8-18)9-10-21-12-16-3-4-16/h5-8,14,16-17,19-20H,3-4,9-13H2,1-2H3/t17-/m0/s1^Y Key:NWIUTZDMDHAVTP-KRWDZBQOSA-N^Y
^NY (what is this?)